Ablative Solutions' TARGET BP I Pivotal Trial Results Demonstrate Significant Reduction in 24-Hour Ambulatory Systolic Blood Pressure Compared to Sham, Using Alcohol-Mediated Renal Denervation
/PRNewswire/ -- Ablative Solutions, Inc., announced that primary trial results from the TARGET BP I Pivotal Trial, evaluating alcohol-mediated renal...
United States Kate Rumrill David Kandzari Ablative Solutions American College Of Cardiology Scientific Congress
Source: prnewswire.com